BIIB: Koefisien rega marang pendapatan Biogen Corp
Growth for Biogen Inc. (BIIB) is driven by the new products Leqembi and Skyclarys, while the development of gene therapy creates future potential. A team of elite neurobiologists relies on generous scientific funding. The revenue valuation on this precise GURU.Markets chart, where 3.70 shows the current metric value, confirms the brand's status as the leading innovator in the treatment of multiple sclerosis.
Rincian analitis perusahaan Biogen Corp (BIIB)
- rega saham lan konsensus proyeksi valuasi:
- informasi kapitalisasi pasar:
- rincian nilai buku perusahaan:
- indikator beban kredit lan likuiditas emiten:
Koefisien Total Utang marang Modal Biogen Inc.|BIIB - Utang jangka dawa marang modal|Utang jangka cendhak marang ekuitas Biogen Idec|BIIB - Gunggung utang perusahaan|Utang-utang marang aset resik Biogen Corp|BIIB - Utang jangka dawa perusahaan|Gunggunge utang jangka cendhak Biogen|Likuiditas cepet biogen.com
- indikator pendapatan resik lan kelipatan nilai:
BIIB - Bathi resik perusahaan|Prakiraan bathi resik Biogen Inc.|BIIB - Pangali P/E|Rasio prakiraan rega marang bathi Biogen Inc|BIIB - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA Biogen Corp|BIIB - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi saben saham sajroning taun lumaku Biogen|BIIB - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham ing petungan tahunan sajrone rolas wulan pungkasan biogen.com|BIIB - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham kanggo taun ngarep Biogen Inc.
- rincian pendapatan lan dodolan emiten:
Analisis umum perusahaan:BIIB, biogen.com
The P/S multiple compares market capitalization to actual sales volume, allowing for an assessment of the value of each unit of revenue regardless of current profitability. The price-to-sales multiple trend for Biogen Inc. (BIIB) reflects market expectations for new R&D developments in neurology, where the risk of losing patent exclusivity could lead to a sharp devaluation of assets and a reduction in the business's investment attractiveness.
Perusahaan pesaing
NBIX (neurocrine.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S RGC (Regencell Bioscience Holdings Limited)|Koefisien rega marang pendapatan Axsome (AXSM)|ACAD - Rasio rega marang pendapatan|XENE (Xenon Corp) - Rasio kapitalisasi marang pendapatan|VKTX: Multiplikator P/S|Kapitalisasi marang pendapatan supernus.com|Kapitalisasi marang pendapatan CPRX|Denali (DNLI) - Koefisien rega marang pendapatan|Multiplikator P/S HRMY|Rasio rega marang pendapatan BHVN (Biohaven Corp)|Multiplikator P/S AMLX (Amylyx Pharmaceuticals)|Koefisien rega marang pendapatan trevitherapeutics.com (TRVI)|Praxis Precision Medicines, Inc. - Multiplikator P/S|Koefisien rega marang pendapatan Anavex AVXL|CBLL: Multiplikator P/S|PRTA (Prothena Corp) - Rasio rega marang pendapatan|Rasio rega marang pendapatan Alector Inc.|Rasio kapitalisasi marang pendapatan ANNX (annexonbio.com)|Multiplikator P/S OMER|NGNE - Rega marang dodolan|AC Immune Corp - Kapitalisasi marang pendapatan|Multiplikator P/S Voyager Corp VYGR|NMRA - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan SCLX (scilexholding.com)|Tevogen Bio (TVGN) - Rasio rega marang pendapatan|Rega marang dodolan Alpha Cognition Inc. (ACOG)|CGTX (Cognition Therapeutics, Inc.) - Multiplikator P/S|Rasio rega marang pendapatan IKT|Multiplikator P/S SAVA|Koefisien rega marang pendapatan assertiotx.com|Rasio rega marang pendapatan Coya Therapeutics COYA|VistaGen Therapeutics, Inc. (VTGN) - Rega marang dodolan|Ovid Rx - Multiplikator P/S|Multiplikator rega marang pendapatan Acumen Pharmaceuticals, Inc (ABOS)|CRVO: Multiplikator P/S|Rega marang dodolan Alterity Therapeutics Limited (ATHE)|Rasio rega marang pendapatan Clene Inc|Rasio kapitalisasi marang pendapatan PEPG (PepGen Corp)|Kapitalisasi marang pendapatan JUNS (Jupiter Neurosciences)|RLMD (Relmada Corp) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S ANVS (Annovis Bio, Inc.)|Koefisien rega marang pendapatan Grace Therapeutics Inc (GRCE)|AIFF - Rasio rega marang pendapatan|KLTO (Klotho Neurosciences Inc) - Rasio kapitalisasi marang pendapatan|NRSN: Multiplikator P/S|Kapitalisasi marang pendapatan Reviva Pharmaceuticals, Inc.|Kapitalisasi marang pendapatan MTVA|neuraxis.com (NRXS) - Koefisien rega marang pendapatan|Multiplikator P/S HSDT|Rasio rega marang pendapatan PASG (passagebio.com)|Multiplikator P/S NEUP (Neuphoria Therapeutics)|Koefisien rega marang pendapatan Minerva (NERV)|Athira Pharma, Inc. - Multiplikator P/S|Koefisien rega marang pendapatan addextherapeutics.com ADXN|ALZN: Multiplikator P/S|CYCN (Cyclerion Therapeutics, Inc.) - Rasio rega marang pendapatan|Rasio rega marang pendapatan Protagenic Therapeutics Inc.|Rasio kapitalisasi marang pendapatan KTTA (Pasithea)|Multiplikator P/S CRGT|ATXI - Rega marang dodolan|BrainStorm Cell Therapeutics - Kapitalisasi marang pendapatan|Multiplikator P/S Cara Therapeutics Inc. CARA|CHRO - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan ELYM (Eliem Therapeutics)|intracellulartherapies.com (ITCI) - Rasio rega marang pendapatan|Rega marang dodolan longboardpharma.com (LBPH)|MRNS (Marinus Pharmaceuticals, Inc.) - Multiplikator P/S|Rasio rega marang pendapatan NKGN|Multiplikator P/S NRBO|Koefisien rega marang pendapatan Sage Therapeutics Inc|Rasio rega marang pendapatan Synaptogenix, Inc. SNPX|trevena.com (TRVN) - Rega marang dodolan|Vigil Neuro - Multiplikator P/S|Multiplikator rega marang pendapatan anewmeds.com (WENA)|CERE: Multiplikator P/S
